Home
Resources
Publications
Discovery of the Highly Potent PI3K/mTOR Dual Inhibitor PF-04979064 Through Structure-Based Drug Design

Discovery of the Highly Potent PI3K/mTOR Dual Inhibitor PF-04979064 Through Structure-Based Drug Design

Hengmiao Cheng, Chunze Li, Simon Bailey, Sangita M Baxi, Lance Goulet, Lisa Guo, Jacqui Hoffman, Ying Jiang, Theodore Otto Johnson, Ted W Johnson, Daniel R Knighton, John Li, Kevin K-C Liu, Zhengyu Liu, etc.

ACS Med Chem Lett. 2012 Nov 7;4(1):91-7.

PMID: 24900568

Abstract:

PI3K, AKT, and mTOR are key kinases from PI3K signaling pathway being extensively pursued to treat a variety of cancers in oncology. To search for a structurally differentiated back-up candidate to PF-04691502, which is currently in phase I/II clinical trials for treating solid tumors, a lead optimization effort was carried out with a tricyclic imidazo[1,5]naphthyridine series. Integration of structure-based drug design and physical properties-based optimization yielded a potent and selective PI3K/mTOR dual kinase inhibitor PF-04979064. This manuscript discusses the lead optimization for the tricyclic series, which both improved the in vitro potency and addressed a number of ADMET issues including high metabolic clearance mediated by both P450 and aldehyde oxidase (AO), poor permeability, and poor solubility. An empirical scaling tool was developed to predict human clearance from in vitro human liver S9 assay data for tricyclic derivatives that were AO substrates.

Chemicals Related in the Paper:

Catalog Number	Product Name	Structure	CAS Number	Price
AP1220699068	PF-04979064		1220699-06-8	Price

As a specialist in analytical chemical Products, Alfa Chemistry offers consumers a wealth of raw materials and a full range of technologies and services.

QUICK LINKS

HEADQUARTERS

Tel:

Fax:

Email: